Skip to main content
Premium Trial:

Request an Annual Quote

Washington University Geneticist, US Genomics Ink Deal to Develop Linear DNA Analysis

NEW YORK, Feb. 21 - Washington University School of Medicine geneticist and dermatologist Pui-Yan Kwok has arranged a deal with US Genomics to use and develop the company's linear DNA analysis method.


Under this partnership, announced on Wednesday, Kwok will adapt US Genomics' direct linear DNA analysis technology to generate new sequence data and explore and map areas of interest. He will also work to extend the company's technology into other applications in genetics.


The company did not disclose financial details of the arrangement.


Kwok's research is focused on identifying new markers associated with complex genetic traits and diseases, and speeding up discovery of polymorphisms and sequence variations.


His group at Washington University is trying to identify polymorphisms by capturing heteroduplex DNA fragments prior to cloning, and by comparing sequence segments generated by the various efforts in the Human Genome Project to identify significant individual differences.


US Genomics, based in Woburn, Mass., has a core technology that allows for high-speed reading of long strands of DNA. The firm also has a research collaboration with the Wellcome Trust Sanger Institute.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.